Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2011 Aug 22;10(10):1807–1817. doi: 10.1158/1535-7163.MCT-11-0362

Figure 6. NSC 47147 chemosensitizes A549 lung cancer cells to cisplatin induced apoptosis.

Figure 6

(A, B) A549 cells were preincubated with 10 μM cisplatin for 24 hours followed by increasing concentrations of NSC 47147 or Bortezomib for 24 hours. ATP levels following treatment were quantified using Promega Cell Titer Glo. Data shows inhibition of NF-κB by NSC 47147 or bortezomib in combination with cisplatin leads to greater cell death as compared to NSC 47147 or bortezomib alone (* P ≤ 0.05). (C) A549 lung cancer cells treated with NSC 47147 in the absence of presence of cisplatin were subjected to cell cycle analysis. Data shows more cells in sub-G1 with NSC 47147/cisplatin combination therapy (12.3%) as compared to control (1.8%), NSC 47147 (1.6%) and cisplatin alone (5.2%). (D) A549 cells treated with NSC 47147, cisplatin or both agents were evaluated for inhibition of pFADD levels and induction of apoptosis by assessing the levels of cleaved caspase-3.